The Effects of Aerobic Exercises on Exercise Capacity in Type-2 Diabetes Mellitus
The Effect of Supervised Exercise Programs on Exercise Capacity and Pulmonary Capacity in Type-2 Diabetic Patients
1 other identifier
interventional
28
1 country
1
Brief Summary
Diabetes, beyond glycemic control, is a complex chronic disease that requires continuous medical care with multifactorial risk reduction strategies. It is necessary to reduce the likelihood of complications and additional problems that may develop in the long term. For this reason, guiding the patient to manage the disease process, equipping and supporting the patient with the necessary information is critical to prevent acute problems. Exercise is the primary treatment method for diabetes patients. Exercise; It is the main treatment method used to increase aerobic capacity and improve respiratory capacity due to the positive effect it has on the body's structure and systems.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2019
CompletedFirst Submitted
Initial submission to the registry
March 27, 2020
CompletedFirst Posted
Study publicly available on registry
April 2, 2020
CompletedApril 9, 2020
April 1, 2020
1 month
March 27, 2020
April 7, 2020
Conditions
Outcome Measures
Primary Outcomes (15)
Incremental Shuttle Walk Test-ISWT
Aerobic Capacity
Baseline Assessment
Incremental Shuttle Walk Test-ISWT
Aerobic Capacity
End of the exercise period assessment (end of the 6. weeks)
Incremental Shuttle Walk Test-ISWT
Aerobic Capacity
End of the follow-up period assessment (end of the 12. weeks)
Digital Spirometer
FVC parameters were evaluated automatically.
Baseline Assessment
Digital Spirometer
FVC parameters were evaluated automatically.
End of the follow-up period assessment (end of the 6. weeks)
Digital Spirometer
FVC parameters were evaluated automatically.
End of the follow-up period assessment (end of the 12. weeks)
Digital Spirometer
FEV1 were evaluated automatically.
Baseline Assessment
Digital Spirometer
FEV1 were evaluated automatically.
End of the follow-up period assessment (end of the 6. weeks)
Digital Spirometer
FEV1 were evaluated automatically.
End of the follow-up period assessment (end of the 12. weeks)
Digital Spirometer
FEV1/FVC were evaluated automatically.
Baseline Assessment
Digital Spirometer
FEV1/FVC were evaluated automatically.
End of the follow-up period assessment (end of the 6. weeks)
Digital Spirometer
FEV1/FVC were evaluated automatically.
End of the follow-up period assessment (end of the 12. weeks)
Digital Spirometer
PEF parameters were evaluated automatically.
Baseline Assessment
Digital Spirometer
PEF parameters were evaluated automatically.
End of the follow-up period assessment (end of the 6. weeks)
Digital Spirometer
PEF parameters were evaluated automatically.
End of the follow-up period assessment (end of the 12. weeks)
Study Arms (2)
The HIIT Group (High Intensity Interval Training Group)
EXPERIMENTALThe MICT Group (Moderate Intensity Continous Training Group)
EXPERIMENTALInterventions
Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
Eligibility Criteria
You may qualify if:
- patients with type-2 diabetes mellitus,
- patients who have sedentary lifestyle (\<3 bouts of exercise per week and \<30 minutes aerobic exercise period),
- non-smoking patients,
- not to lose more than 5% of total body weight in the last 6 months,
- blood pressure\<160/100 mmHg
You may not qualify if:
- alcohol addiction in the last 12 months,
- patients who use insulin hormone,
- patients who have neuropathy or retinopathy,
- patients who have an acute cardiac event in the last 6 weeks,
- patients who have a disease at least 2 weeks in the last 1 month
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emresenocaklead
Study Sites (1)
Marmara University
Istanbul, 34083, Turkey (Türkiye)
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Research Assistant
Study Record Dates
First Submitted
March 27, 2020
First Posted
April 2, 2020
Study Start
February 1, 2019
Primary Completion
March 15, 2019
Study Completion
May 1, 2019
Last Updated
April 9, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share